Glenmark's pain compound set for Phase I in the UK
This article was originally published in Scrip
Executive Summary
Glenmark Pharmaceuticalshas filed to start Phase I trials of GRC 15300, its investigational compound for osteoarthritic, neuropathic and other inflammatory pain with the UK's Medicines and Healthcare products Regulatory Agency. The compound, a transient receptor potential vanilloid (TRPV)3 antagonist, is being developed in neuropathic pain as the primary indication.